Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Declares Quarterly Dividend.
Date:11/8/2011

ST. LOUIS, Nov. 8, 2011 /PRNewswire/ -- Sigma-Aldrich® (NASDAQ: SIAL) -- At the Board of Directors meeting held today, the Directors declared a quarterly cash dividend of $.18 per share.  The dividend is payable on December 15, 2011 to shareholders of record on December 1, 2011.

The Board of Directors also approved a ten million share increase in the Company's repurchase authorization.  This action brings the total authorization to 110 million shares of which 97.625 million shares have been acquired.  Shares repurchased are held as treasury shares.  The Company expects to offset the dilutive impact of issuing share based compensation with future repurchases.  The Company expects to repurchase the 12.375 million remaining authorized shares, but the timing and number of shares purchased, if any, depends upon market conditions and other factors.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing.  We have customers in life science companies, university and government institutions, hospitals and in industry.  Over one million scientists and technologists use our products.  Sigma-Aldrich operates in 40 countries and has over 8,300 employees providing excellent service worldwide.  We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit our award winning web site at www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
3. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
4. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
6. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
7. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
8. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... PHILADELPHIA , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immune system to find a better treatment for triple negative ... Start in France program. ... is an accelerator designed to help entrepreneurs grow their business ... was one of eight American companies selected to complete an ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):